Depression of murine natural killer cell cytotoxicity by isobutyl nitrite. NLM AIDSLINE Important note: Information in this article was accurate in 1984. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Depression of murine natural killer cell cytotoxicity by isobutyl nitrite.

Cancer Immunol Immunother. 1984;17(2):130-4. Unique Identifier : AIDSLINE MED/84282319
Lotzova E; Savary CA; Hersh EM; Khan AA; Rosenblum M

Abstract: We have investigated the effect of isobutyl nitrite on murine NK-cell antitumor-directed cytotoxicity. This agent has been suggested as one of the factors underlying immunodeficiency syndrome (AIDS) in man. We demonstrated that two injections, each of 0.25 ml isobutyl nitrite, resulted in significant depression of endogenous splenic and peripheral blood natural killer (NK) cell cytotoxicity against T-cell lymphoma, YAC-1. In addition to endogenous NK cells, activity of pyrimidinol-activated NK cells was also substantially depressed by this agent. The latter observation is of the utmost importance, since it suggests that the attempt to augment NK-cell activity (to promote resistance to infections and malignancies) could fail in patients with AIDS who are isobutyl nitrite users. Isobutyl nitrite was NK-cell-suppressive not only after in vivo administration but, most importantly, also after inhalation. This indicates that isobutyl nitrite, via its NK-cell suppressive effect, could contribute to immunodeficiency in AIDS. Studies on the mechanism of NK-cell depression by isobutyl nitrite demonstrated that the NK-cell tumor-binding properties as well as NK-cell cytotoxic potential were substantially depressed. Mixing experiments failed to reveal any regulation by suppressor cell activities. The results of these studies clearly indicate that isobutyl nitrite is an immunosuppressive agent and that its use should be avoided.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Animal Cytotoxicity, Immunologic/*DRUG EFFECTS Disease Models, Animal Female Human Immunosuppressive Agents/*PHARMACOLOGY Killer Cells, Natural/*IMMUNOLOGY Lymphocyte Transformation/DRUG EFFECTS Lymphoma/IMMUNOLOGY Mice Nitrites/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Spleen/CYTOLOGY Support, U.S. Gov't, P.H.S. T-Lymphocytes, Suppressor-Effector/IMMUNOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/immunologyanimalcytotoxicity,immunologic/KWDdrugeffectsdiseasemodels,animalfemalehumanimmunosuppressiveagents/KWDpharmacologykillercells,natural/KWDimmunologylymphocytetransformation/drugeffectslymphoma/immunologymicenitrites/administration&dosage/KWDpharmacologyspleen/cytologysupport,uKWDsKWDgov't,pKWDhKWDsKWDt-lymphocytes,suppressor-effector/immunologyjournalarticle
841230
M84C0049

Copyright © 1984 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1984. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1984. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .